Compare Stocks → The asset beating inflation by 4x (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:CRDFNASDAQ:CSBRNASDAQ:GMDANASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ACRDFCardiff Oncology$3.52-21.4%$4.57$0.94▼$6.42$157.38M2.02798,807 shs2.16 million shsCSBRChampions Oncology$5.13+5.3%$10.15$7.19▼$14.68$69.72M0.42,336 shs668 shsGMDAGamida Cell$0.01$0.17$0.03▼$2.51$2.23M0.939.20 million shs858,203 shsOTLKOutlook Therapeutics$8.60+1.2%$8.55$4.00▼$40.60$111.91M0.28251,147 shs101,290 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%+0.00%+0.00%+0.00%CRDFCardiff Oncology-21.43%-13.51%-33.96%+121.38%+89.25%CSBRChampions Oncology+5.36%+0.79%+6.65%-13.78%+1.79%GMDAGamida Cell-3.65%-19.44%-63.75%-95.87%-99.09%OTLKOutlook Therapeutics+1.18%+2.02%-5.70%+18.07%-61.61%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACRDFCardiff Oncology0.9216 of 5 stars3.52.00.00.01.90.00.0CSBRChampions Oncology3.404 of 5 stars3.32.00.04.60.62.50.0GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics2.4707 of 5 stars3.44.00.00.01.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/ACRDFCardiff Oncology3.00Buy$10.50198.30% UpsideCSBRChampions Oncology2.50Moderate Buy$7.5046.20% UpsideGMDAGamida Cell2.75Moderate Buy$4.7532,658.62% UpsideOTLKOutlook Therapeutics2.88Moderate Buy$46.43439.83% UpsideCurrent Analyst RatingsLatest GMDA, AYLA, CSBR, CRDF, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/6/2024CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $14.003/1/2024CRDFCardiff OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21CRDFCardiff Oncology$490K321.18N/AN/A$1.56 per share2.26CSBRChampions Oncology$53.87M1.29N/AN/A$0.34 per share15.09GMDAGamida Cell$1.78M1.25N/AN/A($0.02) per share-0.73OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ACRDFCardiff Oncology-$41.44M-$0.90N/AN/AN/A-6,594.92%-51.54%-45.11%8/14/2024 (Estimated)CSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)GMDAGamida Cell-$63M-$0.63N/A∞N/AN/AN/A-57.59%5/20/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest GMDA, AYLA, CSBR, CRDF, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q3 2024CSBRChampions OncologyN/A-$0.19-$0.19-$0.19N/A$12.02 million2/29/2024Q4 2023CRDFCardiff Oncology-$0.26-$0.21+$0.05-$0.21$0.08 million$0.16 million2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28CRDFCardiff OncologyN/A7.417.41CSBRChampions OncologyN/A0.600.60GMDAGamida Cell213.142.162.09OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%CRDFCardiff Oncology16.29%CSBRChampions Oncology41.30%GMDAGamida Cell50.34%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%CRDFCardiff Oncology6.30%CSBRChampions Oncology45.69%GMDAGamida Cell3.40%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableCRDFCardiff Oncology3144.71 million41.89 millionOptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableGMDA, AYLA, CSBR, CRDF, and OTLK HeadlinesSourceHeadlineGlobal $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging Marketsfinance.yahoo.com - May 3 at 3:15 AMHow to fix Microsoft Outlookmsn.com - May 3 at 3:15 AMOutlook Therapeutics® to Present at the Retina World Congress 2024globenewswire.com - May 2 at 9:05 AMEconomic Outlook Conference to be held Monday on CWU campuscwu.edu - May 1 at 8:40 PMCEOs and Investors Navigate Shifting Economic Terrain: Outlook Revealed in EY CEO Pulse Surveynews.europawire.eu - May 1 at 3:40 PMOutlook News Wrap, May 1: 100 Schools In Delhi Get Bomb Threat, Heatwave Alert Issued Amid 47 Deg Temperature, Split In Godrej & Moreoutlookindia.com - May 1 at 9:56 AMQ1 2024 CA Auto Outlook: Tesla registrations drop; Sales slip 7.8% YTDivpressonline.com - April 30 at 2:18 PMNatural Gas News: Freeport LNG Resumption Brightens Outlookfxempire.com - April 29 at 1:15 PMOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcaseglobenewswire.com - April 29 at 9:00 AMThese 5 programs are way better than Microsoft Outlookmsn.com - April 29 at 8:15 AMHCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 Outlookusnews.com - April 29 at 8:15 AMShort Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Declines By 15.0%americanbankingnews.com - April 29 at 2:18 AMBest's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation Councilfinance.yahoo.com - April 29 at 1:28 AMBulgaria's Eurozone Aspirations: Fitch Ratings Affirms Positive Outlooknovinite.com - April 27 at 7:18 AMOutlook Magazine's Reporters Guarantee: Editor's Exclusiveoutlookindia.com - April 27 at 2:18 AMOutlook man accused of dragging girlfriend with his caryakimaherald.com - April 27 at 2:18 AMGlobal Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036finance.yahoo.com - April 26 at 4:17 PMHow to Use Copilot in Outlookmsn.com - April 26 at 4:17 PMOutlook's Next Issue: Inside The Election Cauldronoutlookindia.com - April 26 at 4:17 PMMedia advisory - OECD Economic Outlook 2024oecd.org - April 26 at 6:16 AMBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positivefinance.yahoo.com - April 22 at 1:21 PMUSD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlookfxempire.com - April 22 at 1:21 PMWGA Releases New Housing Finance Outlookmarkets.businessinsider.com - April 22 at 1:21 PMOutlook Money’s Tushar Ghosh elevated to Publishing Directorpitchonnet.com - April 22 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Cardiff OncologyNASDAQ:CRDFCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.